NCT03392064View on ClinicalTrials.gov

A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC

PHASE1SuspendedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 10, 2018

Primary Completion Date

January 14, 2028

Study Completion Date

January 14, 2028

Conditions
Small Cell Lung Cancer
Interventions
BIOLOGICAL

AMG 119

Investigational, adoptive cellular immunotherapy for the treatment of small cell lung cancer

Trial Locations (2)

33612

Research Site, Tampa

77030

Research Site, Houston

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03392064 - A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC | Biotech Hunter | Biotech Hunter